Shares of

Kos Pharmaceuticals

( KOSP) were among the best-performing health and pharmaceutical stocks Thursday after the company posted better-than-expected second-quarter financial results and told Wall Street that its full-year earnings and sales would beat expectations.

Excluding items, the pharmaceuticals company posted second-quarter earnings of 70 cents a share on sales of $120.3 million. Analysts surveyed by Thomson First Call had expected it to earn 54 cents a share on sales of $115.2 million. Looking ahead, it forecast full-year earnings of $2.60 a share to $2.65 a share on sales of about $480 million. Analysts were looking for earnings of $2.50 a share on sales of $478 million. Shares of Kos Pharmaceuticals were recently trading up $6.06, or 21.1%, to $34.81.

Kindred Healthcare

( KIND) rose after it posted better-than-expected second-quarter earnings and raised its full-year outlook. The health care company posted a second-quarter profit of 58 cents a share on sales of $897.5 million. Analysts had expected it to earn 40 cents a share on sales of $869.1 million. Looking ahead, the company forecast full-year earnings of $1.88 a share to $1.95 a share. Previously, it had expected earnings of $1.58 a share to $1.74 a share. Analysts were looking for $1.70 a share. Kindred also said sales would be at the top range of its previous guidance of $3.5 billion to $3.6 billion. Analysts were looking for $3.54 billion. Shares were recently trading up $2.33, or 9.9%, to $25.87.

Shares of

Kyphon

( KYPH) rose after the company posted better-than-expected second-quarter earnings and sales and said that full-year results would top analysts' forecasts. The medical device marketer earned 11 cents a share during the second quarter on sales of $50.7 million. Analysts had expected earnings of 8 cents a share on sales of $49 million. Looking ahead, Kyphon expects full-year earnings of 44 cents a share to 46 cents a share on sales of $210 million to $212 million. Analysts were looking for 42 cents a share on sales of $201.7 million. Shares of Kyphon were recently trading up $3.02, or 12.1%, to $28.01.

Nymox Pharmaceutical

(NYMX) - Get Report

fell after it said the Food and Drug Administration raised issues with the company's clinical study methodology for its NTP test kit, and said that its premarket approval application is not approvable in its current form. The company may file an amendment providing more clinical study data, request an administrative review, or withdraw the premarket approval application altogether. In particular, the FDA raised an issue with clinical methodology at one of its nine clinical study centers. The company is hopeful the issue can be resolved and that it can get its application approved. Shares of Nymox Pharmaceuticals were recently trading down 84 cents, or 26.2%, to $2.37.

Shares of

Valeant Pharmaceuticals

(VRX)

rose after the company posted better-than-expected second-quarter earnings and in-line sales. Excluding items, the specialty pharmaceutical company earned 2 cents a share on sales of $170.4 million. Analysts had expected it to post a loss of a penny on sales of $170.4 million. Shares were recently trading up $1.52, or 8.4%, to $19.57.

Other health care volume movers included

Nektar Therapeutics

(NKTR) - Get Report

, down $5.54 to $11.05;

Schering-Plough

( SGP), up 8 cents to $18.04;

Pfizer

(PFE) - Get Report

, down 46 cents to $31.94;

Johnson & Johnson

(JNJ) - Get Report

, up 32 cents to $55.90; and

Amgen

(AMGN) - Get Report

, down 35 cents to $56.20.